U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797336) titled 'A Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors' on Jan. 22.
Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.
Study Start Date: Jan., 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: PT0253
PT0253 injection.
Recruitment Status: RECRUITING
Sponsor: PAQ Therapeutics, Inc.
Disclaimer: Curated by HT Syndica...